tate tissue, respectively) than in the control group (6.10 pg/mg) (overall, P<.001); by contrast, testosterone was higher in the 200-ppm diet group (2.09 pg/mg) than in the control group (1.08 pg/mg) or the 20-ppm diet group (1.21 pg/mg) (overall, P<.001). Conclusions: FK143, when fed to rats at 20 or 200 ppm, significantly reduced the level of dihydrotestosterone in their prostate tissue. However, the incidence of macroscopic cancer in the prostate was suppressed in rats consuming the 20 ppm FK143-containing diet but not in those consuming the 200-ppm diet. The lack of dose dependence for the chemopreventive activity of FK143 may be explained by the reciprocal increase of tissue testosterone in the 200-ppm diet group. Implications: The 5␣-reductase inhibitor FK143 may, at specific doses, reduce the incidence of spontaneously developing prostate cancer; however, whether these findings in rats will apply to humans remains to be determined. [J Natl Cancer Inst 1997;89:
803-7]
In most western countries, prostate cancer is one of the leading causes of cancer-related death in men (1) . Strategies to reduce mortality from this disease include early detection (2) or therapeutic advances (3), although primary prevention would be the ideal strategy (4) .
The clues to cancer prevention may be found in the epidemiologic characteristics of prostate cancer. Asian people who emigrate to western countries show a much higher mortality from prostate cancer than those who remain in their homelands (5, 6) . On the contrary, the prevalence of latent or preclinical prostate cancer is less variable worldwide (7) . These findings suggest environmental or epigenetic influences as the causal factors for clinical prostate cancer (8) ; however, no specific factors have been identified.
The prostate is an androgen-dependent organ (9) , and androgens play an important role in carcinogenesis of the prostate. Exogenous androgen supplementation is required in most animal prostate carcinogenesis models (10, 11) . The higher level of circulating testosterone may explain the higher incidence of prostate cancer in a human population (12, 13) . Clinical prostate cancers often respond to androgen-deprivation therapy. Thus, reduction in androgen levels should affect carcinogenesis processes, although systemic androgen ablation is not acceptable as a preventive measure because of associated male sexual dysfunctions.
In the prostate, testosterone is rapidly and irreversibly converted to 5␣-dihydrotestosterone (14, 15) . This metabolite plays a much more important role than testosterone in the organogenesis and homeostasis of the prostate (9, 16, 17) . The administration of 5␣-reductase inhibitors results in a substantial decrease in prostatic secretion of the normal gland and a substantial increase in cell death in normal and transformed prostatic cells (18) (19) (20) . The racial populations with a higher incidence of prostate cancer were shown to have a higher activity of 5␣-reductase (21, 22) . Also, men with prostatic cancer have an increased conversion rate of testosterone to its potent 5␣-reduced metabolites (23) .
A series of 5␣-reductase inhibitors have been synthesized (20, (24) (25) (26) (27) . Fortunately, 5␣-reductase inhibitors, such as finasteride, while lowering intraprostatic concentration of dihydrotestosterone, do not affect adversely serum testosterone level or sexual functions (28) . These observations provide the rationale for a chemoprevention trial using a 5␣-reductase inhibitor as the preventive medicine, and such a study involving 18 000 men randomly assigned to receive finasteride or placebo has been started in the United States (29, 30) . However, the possible preventive effects of 5␣-reductase inhibitors on prostate carcinogenesis have not been confirmed in in vivo experimental models. Considering the acknowledged importance of the confirmative and exploratory investigations on this matter (31), we performed the present study to determine whether FK143, a nonsteroidal and noncompetitive 5␣-reductase inhibitor (26, 27) , inhibits the development of prostate cancer in rats.
Methods

Animals
ACI/Seg rats (4-6 weeks of age) were purchased from Harlan Industries (Cumberland, IN). Each group of four to six rats was housed in plastic cages with woodchip bedding. The animal room was maintained at a temperature of 22°C ± 2°C and a humidity of 55% ± 15%, with a 12-hour light-12-hour dark cycle. The animal care was in accord with our institutional guidelines.
Chemicals and Diets
-butyric acid) (molecular weight ‫ס‬ 600.8), a nonsteroidal and noncompetitive inhibitor of 5␣-reductase of the human and rat prostate (26, 27) , was a gift from the Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). The agent is mixed with a natural-ingredient basal diet called MK-rat (Oriental Food Corp., Tokyo, Japan) at concentrations indicated.
Experimental Protocol
Preliminary experiment. Fifteen rats (30 weeks of age) were arbitrarily assigned to five groups of three rats each. They were fed diets containing 0, 2, 20, 200, or 2000 ppm FK143 for 2 weeks and were killed immediately after completion of the treatment. Tissue weight and tissue concentrations of testosterone and dihydrotestosterone were measured for the ventral and dorsal lobes separately.
Long-term experiment. One hundred five male ACI/Seg rats (80 weeks of age) were randomly divided into three groups of 35 each and fed either the control diet, the diet containing FK143 at 20 ppm, or the diet containing FK143 at 200 ppm for the following 60 weeks. During the treatment, food and tap water were given ad libitum, and dietary intake was measured during a 1-week period every 4 weeks throughout the experiment. The animals were also weighed every 4-6 weeks. The diets were prepared every 4-6 weeks and stored at 4°C, and the concentration of the chemical was measured by highperformance liquid chromatography for one of every four lots. At the age of 140 weeks, all of the rats were killed by an ether overdose, and the prostate gland was removed.
The left ventral prostate lobe was immediately frozen and kept at −80°C until analysis for androgen contents. When the left lobe harbored macroscopic cancerous lesions, the right lobe was used instead. Prostatic testosterone and dihydrotestosterone concentrations in the tissue extracts were measured by radioimmunoassay according to Albert et al. (32) at the Special Reference Laboratory (Tokyo, Japan). For histologic evaluation, the remaining ventral lobe was fixed in 10% formalin solution. Four sagittal slices (5 m thick) of the ventral lobe were stained with hematoxylin-eosin. The presence of atypical hyperplasia and adenocarcinoma was determined as previously described (33) according to the criteria proposed by Bosland (34) . Briefly, atypical hyperplasia was defined as a focal hyperplastic lesion at least three to five cells thick and involving one or a few alveoli. The lining cells showed no or minimal pleomorphism and tended to be arranged in a cribriform pattern, but the normal alveolar architecture was not disturbed by capsular compression. Adenocarcinoma was defined as epithelial proliferation occupying three or more alveoli with a cribriform or solid growth pattern. The cells were often associated with inflammatory infiltrates. They compressed or sometimes invaded the adjacent alveoli, and the normal architecture was distorted. The assigned group of each rat was not blinded during autopsy; however, histologic evaluations were performed in a blinded fashion independently by two researchers (Y. Homma and Y. Kondo). When the two investigators were found to have made different diagnoses from their examination of a sample, they would discuss the diagnosis and come to agreement before breaking the key.
Statistical Analyses
Statistical analyses were done by use of commercially available computer programs (SAS Institute, Inc., Cary, NC). Student's t test or analysis of variance was used for the comparison of tissue weight and androgen concentrations. The proportions of rats having specific pathologic lesions were compared across the three dose groups by use of the Fisher's exact test. When a significant (P<.05) difference was found, individual group comparisons were also performed by use of the Fisher's exact test. The P values for these comparisons were the results from two-sided tests and adjusted by use of a permutation-style resampling method to control the false-positive error rate associated with the multiple tests.
Results
In the preliminary experiment (Table  1) , the mean body weight gain for the rats over 2 weeks was 13-16 g in all groups, except for the group fed the 2000-ppm FK143 diet, in which the gain was 3 g. The response of the prostate ventral lobe to the chemical was clearly distinct between the rat groups fed diets containing 0 (i.e., control group), 2, or 20 ppm FK143 (lower dose groups) and those fed diets containing 200 or 2000 ppm of the compound (higher dose groups). The mean values of wet weight, dihydrotestosterone concentration, and testosterone concentration were 0.23 and 0.2 g, 46.0 and 48.9 pg/mg wet weight, and 0.81 and 1.54 pg/mg wet weight, respectively, in the ventral lobes of animals in the two lower dose groups. The corresponding figures in the higher dose groups were 0.13 and 0.1 g, 16.3 and 16.9 pg/mg wet weight, and 9.57 and 11.03 pg/mg wet weight, respectively. In comparison between the lower dose and higher dose groups, the tissue weight and dihydrotestosterone level were lower, and by contrast, the testosterone content was higher in the higher dose groups. Similar observations were noted in the dorsal lobes; however, the difference between the lower dose and higher dose groups was not so evident as in the ventral lobes.
In the long-term experiment, one rat in the 200-ppm diet group died at 102 weeks because of unidentified reasons. The mean (± standard deviation [SD]) body weight of rats was 368.4 (± 29.1) g at the start of the experiment and showed almost no change thereafter (data not shown). The final weights (mean ± SD) were 384.6 g ± 38.2 g, 375.8 g ± 41.5 g, and 375.4 g ± 40.9 g in the control diet, the 20-ppm diet, and the 200-ppm diet groups, respectively (P ‫ס‬ .882). The daily consumption of the diets was also similar among the groups, although it declined from approximately 15 g per rat during the first week to 12 g per rat during 
, respectively. The assay of the dietary concentration of FK143, which was performed three times during the experiment, yielded 86%-112% of the expected dose.
Histopathologic examination of the ventral lobes revealed that the incidence of macroscopic cancer was 17.1%, 0%, and 23.5% in the control diet group, the 20-ppm diet group, and the 200-ppm diet group, respectively ( Table 2 ). The incidences differed significantly among the three groups (P ‫ס‬ .004), and the incidence in the 20-ppm diet group was significantly lower than that in the control group (P ‫ס‬ .029) or that in the 200-ppm diet group (P ‫ס‬ .003). The frequency of rats bearing macroscopic and/or microscopic carcinoma, although lowest in the 20-ppm diet group (45.7%) followed by the control group (62.9%) and the 200-ppm diet group (67.6%), showed no statistically significant difference among them (P ‫ס‬ .153). The frequency of atypical hyperplasia was uniformly high in all three groups (>90%).
From the measurement of intraprostatic androgen concentrations, it was found that there was a statistically significant suppression of dihydrotestosterone in the rats of both treated groups (4.51 and 4.33 pg/mg wet weight) compared with those of the control group (6.10 pg/mg) (P<.001); however, the difference between the two treated groups was not significant (P ‫ס‬ .887). In contrast, the testosterone level was significantly increased in the 200-ppm diet group (2.09 pg/mg wet weight) compared with the control group (1.08 pg/mg) (P<.001) and the 20-ppm diet group (1.21 pg/mg) (P<.001), and there was no significant difference between the 20-ppm diet group and the control group (P<.684). In short, the level of dihydrotestosterone was reduced in both treated groups to a similar extent, whereas the level of testosterone was increased only in the high-dose group. Another important finding was that the mean concentration of dihydrotestosterone in the 140-week-old control rats (6.10 pg/mg) was much lower than that in the 32-week-old control rats (52.3 pg/mg), whereas the mean concentrations of testosterone were almost the same between these two groups of animals (1.08 and 1.24 pg/mg, respectively).
Discussion
Prostate cancer is highly prevalent in men of European and North American countries (1), and an effective preventive modality is urgently needed (4). Evidence from epidemiologic (5-8), biologic (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , and clinical (28) studies supports the rationale for prostate cancer prevention by 5␣-reductase inhibitors (4, 29, 30) , although a long-term in vivo animal experiment has never been conducted.
In this investigation, we performed such an experiment using ACI/Seg rats, which develop prostate cancer spontaneously (35) , and a 5␣-reductase inhibitor, FK143.
In the preliminary study, we found that the diet containing 200 or 2000 ppm FK143, when given to 30-week-old rats for 2 weeks, resulted in reduction of dihydrotestosterone content and reciprocal accumulation of testosterone in the ventral lobe; in parallel experiments, rats fed diets containing either 2 or 20 ppm FK143 did not manifest changes in dihydrotestosterone or testosterone content. These findings were compatible with previous observations (27) . Since the body weight gain seemed to be somewhat less in the rats treated with the 2000-ppm diet, the intermediate two doses of 20 and 200 ppm were selected for the long-term study.
In the long-term study, the special diets were administered to rats between 80 and 140 weeks of age. No systemic toxicity was apparent. The frequencies of rats developing prostate carcinomas and macroscopic lesions were 62.9% and 17.1%, respectively, in the control group. These figures were lowered in the 20-ppm FK143 group (45.7% and 0%, respectively) and increased in the 200-ppm FK143 group (67.6% and 23.5%, respectively). The difference in the incidences of rats having microscopic and/or macroscopic prostate carcinoma was not statistically significant (P ‫ס‬ .153), whereas the difference in incidences of macroscopic cancer was statistically significant between the control group and the 20-ppm group (P ‫ס‬ .029) and between the 20-ppm group and the 200-ppm group (P ‫ס‬ .003). Atypical hyperplasia was observed in the prostates of more than 90% of the animals in each of the three groups.
Intraprostatic androgen determination showed that there was a statistically significant decrease in dihydrotestosterone in both the treated groups (4.51 and 4.33 pg/mg wet weight) compared with the control group (6.10 pg/mg) (P<.001) and a significant increase in testosterone in the 200-ppm diet group (2.09 pg/mg) (P<.001). The difference in testosterone content between the 20-ppm diet group (1.21 pg/mg) and the control diet group (1.08 pg/mg) was not significant (P ‫ס‬ .684). Another important finding was that dihydrotestosterone concentration was much lower in 140-week-old control rats than in those aged 32 weeks. Testosterone, pg/mg wet weight ‡ 1.08 ± 0.38 1.21 ± 0.42 2.09 ± 0.95 ¶ *Number of rats with the lesions (frequency). †Carcinoma includes either microscopic or macroscopic lesions. ‡Mean ± standard deviation. §Significantly less frequent than 0 (P ‫ס‬ .029) and 200 ppm (P ‫ס‬ .003).
Significantly lower than 20 ppm (P ‫ס‬ .041). ¶Significantly different from the other two groups (P ‫ס‬ .001).
The results in the 20-ppm diet group are compatible with the hypothesis of chemoprevention by 5␣-reductase inhibitors; that is, a 5␣-reductase inhibitor may reduce tissue dihydrotestosterone concentration and prevent prostate carcinogenesis. Less plausible is that the incidence of rats bearing microscopic and/or macroscopic cancer was not significantly reduced, and that atypical hyperplasia was equally highly prevalent among the three groups. These findings suggest that 5␣-reductase inhibitors do not interfere with initiation but affect the postinitiation phase of carcinogenesis. It has been shown that ACI/Seg rats at 80 weeks of age, when this long-term experiment was started, have atypical hyperplasia and microscopic carcinoma in the prostate at prevalences of approximately 60% and 10%, respectively (35) . We chose this age of rats because administration of 5␣-reductase inhibitors to humans would be started when the men are 50 or 60 years old (29, 30) , and at those ages 10%-30% of the men have already developed microscopic cancer (6) . To examine the effect of the starting time of treatment on cancer prevention, we have begun further experiments in which the administration of FK143 to the rats is started at younger ages.
In contrast to the results of the 20-ppm diet group, the rats in the 200-ppm diet group developed prostate cancer at a similar or even higher incidence compared with the control group. In these rats, intraprostatic androgen assays showed a suppression of dihydrotestosterone and an increase in testosterone. The intraprostatic accumulation of testosterone has been observed after treatment with FK143 (27) and other 5␣-reductase inhibitors as well (18, 19, 36, 37) . The accumulation was not noted in the 20-ppm diet group. Although testosterone is much less efficient an androgen than dihydrotestosterone, it can be androgenic if the tissue level is high enough (38) . Thus, it is possible that accumulated testosterone compensated for the reduced concentration of dihydrotestosterone. In addition, prostatic dihydrotestosterone concentration in the control rats remarkably declined with advancing age, while testosterone was rather stable. Therefore, the prostate cancer prevention that could be achieved by suppression of dihydrotestosterone production may become less evident when testosterone is accumulated or the rats are aged. However, further experiments with various doses of this agent and other 5␣-reductase inhibitors are warranted to confirm our findings and elucidate the mechanisms involved.
In conclusion, FK143, a 5␣-reductase inhibitor, prevented the development of macroscopic cancer in the prostates of rats fed a diet containing 20 ppm FK143 but had no such effect in rats fed a diet containing 200 ppm FK143. The failure of the higher dose to prevent the development of prostate cancer may be explained by the reciprocally increased intraprostatic testosterone level and/or age-related changes in hormonal environment in the organ. However, whether these findings in rats will apply to humans remains to be determined. Numerous investigators (1-8) have reported that cytokines are able to potentiate drug activity in multidrug-resistant cell populations. These reports have suggested that the inclusion of cytokine administration in combination-chemotherapy protocols may provide a clinical approach to reversing multidrug resistance. This approach, however, is complicated by the toxic effects associated with systemic administration of cytokines such as tumor necrosis factor-␣ (TNF-␣) (9, 10) . One possible method of administering TNF-␣ that may avoid systemic toxic effects is the direct introduction into
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